Sansure Biotech Inc.

Shanghai Stock Exchange 688289.SS

Sansure Biotech Inc. Revenue for the year ending December 31, 2023: USD 141.85 M

Sansure Biotech Inc. Revenue is USD 141.85 M for the year ending December 31, 2023, a -84.82% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Sansure Biotech Inc. Revenue for the year ending December 31, 2022 was USD 934.72 M, a 31.56% change year over year.
Sansure Biotech Inc. Revenue for the year ending December 31, 2021 was USD 710.50 M, a -2.63% change year over year.
Sansure Biotech Inc. Revenue for the year ending December 31, 2020 was USD 729.69 M, a 1,290.68% change year over year.
Sansure Biotech Inc. Revenue for the year ending December 31, 2019 was USD 52.47 M, a 18.92% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688289.SS

Sansure Biotech Inc.

CEO	Mr. Lizhong Dai
IPO Date	Aug. 28, 2020
Location	China
Headquarters	No. 680, Lusong Road
Employees	2,006
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

Key trends

Past 5 years